OR WAIT null SECS
Steven J. Lynn previously held positions at FDA’s Center for Drug Evaluation and Research, the Center for Devices and Radiological Health, and the Office of Regulatory Affairs.
Regulatory Compliance Associates (RCA), a life sciences consultancy, announced on Sept. 22 that Steven J. Lynn will serve as the company’s new executive vice-president of Pharmaceuticals.
Prior to joining RCA, Lynn held positions at FDA’s Center for Drug Evaluation and Research, the Center for Devices and Radiological Health, and the Office of Regulatory Affairs, a company press release said. Additionally, Lynn worked with leading brand and generic pharmaceutical and biopharma manufacturers and in private consulting for post-market good practice (GxP) quality, compliance, and regulatory affairs.
“RCA clients will benefit from Steve’s expertise with FDA’s insights regarding compliance and regulatory framework and will help them navigate regulatory challenges in the medical product and biologics sectors,” said Erika Porcelli, CEO of RCA, in the press release. “His extensive background spanning industry, consulting, and the FDA gives Mr. Lynn a unique perspective in providing RCA clients with wholistic and seasoned guidance as they bring new life-sustaining medicines to the market as well as maintaining compliance with FDA and other global health authorities’ quality oversight.”